HeartBeam, Inc. (BEAT)

NASDAQ: BEAT · Real-Time Price · USD
0.6754
+0.0354 (5.53%)
At close: Jun 26, 2026, 4:00 PM EDT
0.6700
-0.0054 (-0.80%)
After-hours: Jun 26, 2026, 4:28 PM EDT
Market Cap36.78M -32.0%
Revenue (ttm)n/a
Net Income-20.23M
EPS-0.56
Shares Out 55.51M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume588,633
Open0.6495
Previous Close0.6400
Day's Range0.6342 - 0.6869
52-Week Range0.5400 - 4.0000
Beta-0.87
AnalystsStrong Buy
Price Target3.83 (+477.94%)
Earnings DateAug 12, 2026

About BEAT

HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart’s electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician port... [Read more]

Sector Healthcare
IPO Date Nov 11, 2021
Employees 17
Stock Exchange NASDAQ
Ticker Symbol BEAT
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for BEAT stock is "Strong Buy." The 12-month stock price target is $3.83, which is an increase of 477.94% from the latest price.

Price Target
$3.83
(477.94% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

HeartBeam Proxy statement: Proxy filing

HeartBeam filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.

1 day ago - Filings

HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition.

Other symbols: BEAT
2 days ago - Business Wire

HeartBeam Proxy statement: Proxy filing

HeartBeam filed a proxy statement on June 18, 2026, providing details for shareholder voting and corporate governance matters.

8 days ago - Filings

HeartBeam Proxy statement: Proxy filing

HeartBeam filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.

21 days ago - Filings

HeartBeam Slides: Investor presentation

HeartBeam has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.

21 days ago - Filings

HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home.

Other symbols: BEAT
24 days ago - Business Wire

HeartBeam Earnings Call Transcript: Q1 2026

Achieved key milestones in commercialization, clinical validation, and product development, including flagship accounts in four major geographies and a strategic AI partnership. Q1 2026 saw a 19% year-over-year reduction in cash burn, with a strengthened balance sheet and funding runway into 2027.

6 weeks ago - Transcripts

HeartBeam Quarterly report: Q1 2026

HeartBeam has published its Q1 2026 quarterly earnings report on May 13, 2026.

6 weeks ago - Filings

HeartBeam Slides: Q1 2026

HeartBeam has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.

6 weeks ago - Filings

HeartBeam Earnings release: Q1 2026

HeartBeam released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.

6 weeks ago - Filings

HeartBeam Reports First Quarter 2026 Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports First Quarter 2026 Results.

Other symbols: BEAT
6 weeks ago - Business Wire

HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic.

Other symbols: BEAT
6 weeks ago - Business Wire

HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice.

Other symbols: BEAT
7 weeks ago - Business Wire

HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time.

Other symbols: BEAT
2 months ago - Business Wire

HeartBeam Announces Closing of $10 Million Public Offering of Common Stock

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Closing of $10 Million Public Offering of Common Stock.

Other symbols: BEAT
2 months ago - Business Wire

HeartBeam Slides: Investor presentation

HeartBeam has posted slides in relation to its latest quarterly earnings report, which was published on April 16, 2026.

2 months ago - Filings

HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock.

Other symbols: BEAT
2 months ago - Business Wire

HeartBeam Announces Proposed Public Offering of Common Stock

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Proposed Public Offering of Common Stock.

Other symbols: BEAT
2 months ago - Business Wire

HeartBeam Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference

A novel at-home 12-lead ECG platform is launching with a subscription model targeting concierge cardiology, leveraging strong physician and patient demand. The company is expanding into ambulatory monitoring and AI-driven cardiac care, supported by clinical studies and strategic partnerships.

3 months ago - Transcripts

HeartBeam Registration statement: Registration Filing

HeartBeam filed a registration statement on March 13, 2026, providing details about a securities offering with the SEC.

3 months ago - Filings

HeartBeam Earnings Call Transcript: Q4 2025

FDA clearance for 12-lead ECG software enabled commercial launch and partnerships, with strong demand in concierge cardiology. Net loss narrowed, cash use declined, and 2026 will focus on scaling adoption, clinical studies, and AI development.

3 months ago - Transcripts

HeartBeam Earnings release: Q4 2025

HeartBeam released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.

3 months ago - Filings

HeartBeam Annual report: Q4 2025

HeartBeam has published its Q4 2025 annual report on March 12, 2026.

3 months ago - Filings

HeartBeam Slides: Q4 2025

HeartBeam has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 12, 2026.

3 months ago - Filings

HeartBeam Reports Fourth Quarter and Full Year 2025 Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Fourth Quarter and Full Year 2025 Results.

Other symbols: BEAT
3 months ago - Business Wire